Germany · Delayed Price · Currency is EUR HeraMED Statistics
Total Valuation
HeraMED has a market cap or net worth of EUR 22.32 million. The enterprise value is 21.78 million.
| Market Cap | 22.32M |
| Enterprise Value | 21.78M |
Important Dates
The last earnings date was Friday, November 28, 2025.
| Earnings Date | Nov 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 1.04B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +145.72% |
| Shares Change (QoQ) | +25.03% |
| Owned by Insiders (%) | 9.01% |
| Owned by Institutions (%) | 7.04% |
| Float | 834.61M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 123.78 |
| PB Ratio | 69.39 |
| P/TBV Ratio | 69.39 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -8.60 |
| EV / Sales | 119.66 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -9.77 |
Financial Position
The company has a current ratio of 3.04
| Current Ratio | 3.04 |
| Quick Ratio | 2.33 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2,324.65 |
Financial Efficiency
Return on equity (ROE) is -518.37% and return on invested capital (ROIC) is -253.83%.
| Return on Equity (ROE) | -518.37% |
| Return on Assets (ROA) | -105.38% |
| Return on Invested Capital (ROIC) | -253.83% |
| Return on Capital Employed (ROCE) | -370.65% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.14 |
| Inventory Turnover | 0.38 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +126.92% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +126.92% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.01 |
| Relative Strength Index (RSI) | 50.96 |
| Average Volume (20 Days) | 86,212 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HeraMED had revenue of EUR 180,278 and -2.53 million in losses. Loss per share was -0.00.
| Revenue | 180,278 |
| Gross Profit | 105,830 |
| Operating Income | -2.20M |
| Pretax Income | -2.53M |
| Net Income | -2.53M |
| EBITDA | -2.27M |
| EBIT | -2.20M |
| Loss Per Share | -0.00 |
Balance Sheet
The company has 532,821 in cash and n/a in debt, giving a net cash position of 532,821.
| Cash & Cash Equivalents | 532,821 |
| Total Debt | n/a |
| Net Cash | 532,821 |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 321,577 |
| Book Value Per Share | 0.00 |
| Working Capital | 582,563 |
Cash Flow
In the last 12 months, operating cash flow was -2.26 million and capital expenditures 32,808, giving a free cash flow of -2.23 million.
| Operating Cash Flow | -2.26M |
| Capital Expenditures | 32,808 |
| Free Cash Flow | -2.23M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 58.70% |
| Operating Margin | -1,221.14% |
| Pretax Margin | -1,404.03% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
HeraMED does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -145.72% |
| Shareholder Yield | -145.72% |
| Earnings Yield | -11.34% |
| FCF Yield | -9.99% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
HeraMED has an Altman Z-Score of -36.49 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -36.49 |
| Piotroski F-Score | 2 |